Impact of the coronavirus disease pandemic on robot‐assisted radical prostatectomy and urologists' treatment behaviors: A single tertiary center retrospective study

Abstract

ObjectivesTo assess whether the coronavirus disease (COVID‐19) pandemic affected the outcomes of robot‐assisted radical prostatectomy (RARP) and urologists' treatment behaviors.MethodsWe retrospectively examined the medical records of 208 patients who had undergone RARP between August 2017 and December 2022. We compared the rate of preoperative androgen deprivation therapy (ADT), waiting period for RARP, patients' baseline characteristics and quality of life (QOL), proportion of adverse pathology on the RARP specimen, rate of Gleason grade group upgrading from biopsy to the RARP specimen, and prostate‐specific antigen (PSA) recurrence‐free survival between the pre‐pandemic and pandemic groups.ResultsThe rate of preoperative ADT was significantly higher during than before the COVID‐19 pandemic (13.7% vs. 1.9%; p = 0.002). The baseline physical and mental QOL scores did not differ significantly between the groups. The proportion of D'Amico low‐risk patients was significantly lower (13.6% vs. 1.2%, p = 0.005) and waiting period for RARP was significantly shorter (median 3.5 months vs. 4.0 months, p = 0.016) in the pandemic group than in the pre‐pandemic group. There was no significant difference in the proportion of adverse pathology between the groups (p = 0.104); however, the upgrading rate was significantly higher in the pre‐pandemic group (p = 0.002). There was no significant difference in PSA recurrence‐free survival between the groups (log‐rank, p = 0.752).ConclusionsThe COVID‐19 pandemic did not adversely affect the oncologic outcomes of RARP and QOL before RARP. However, it caused urologists to increase the use of preoperative ADT and to reserve RARP for higher‐risk cases.